RxDoctor Payments Data

Barry Smith, MD

Dermatology · New York, NYNPI 1770568073

Payments from drug & device makers

$8,765in general payments, 2019–2025

Across 155 payments — averaging $56.55 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Sun Pharmaceutical Industries Inc.$3K
  • Galderma Laboratories, L.p.$2K
  • E.r. Squibb & Sons, L.L.C.$1K
  • Incyte Corporation$712
  • Amgen$357
  • AbbVie$321
  • plus $1K from 13 others

What the payments were for

  • Consulting fees$4,42550%
  • Travel & lodging$581%
  • Food & beverage$4,21048%
  • Education$721%

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,765 in reported general payments places this provider in the 70th percentile of 1,151 dermatology providers in New York.

See all dermatology providers in New York

Medicare billing

Part B allowed, 2024
$51,843
Medicare patients
297
Services billed
627

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OtezlaApremilast20$96,844
Dupixent PenDupilumab27$96,823
Dupixent SyringeDupilumab23$84,254
OpzeluraRuxolitinib Phosphate24$46,179
TazoracTazarotene13$22,023
Clobetasol Propionate78$5,677
Fluocinonide124$4,840
Calcipotriene12$2,698
Triamcinolone Acetonide223$2,660
Betamethasone Dipropionate58$2,232
Tretinoin24$2,119
Ketoconazole111$1,785
Doxycycline Hyclate51$1,545
Halobetasol Propionate24$1,207
Clindamycin Phosphate31$1,016

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AmgenOtezla$357$96,84420 claims
Incyte CorporationOpzelura$712$46,17924 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 1,151 dermatology providers in New York.

Other dermatology in New York

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →